1IY Stock Overview
A clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Monopar Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.85 |
| 52 Week High | US$7.25 |
| 52 Week Low | US$1.20 |
| Beta | 1.18 |
| 11 Month Change | -41.73% |
| 3 Month Change | -41.73% |
| 1 Year Change | -40.32% |
| 33 Year Change | -90.16% |
| 5 Year Change | n/a |
| Change since IPO | -96.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1IY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -32.7% | 2.0% | 1.9% |
| 1Y | -40.3% | -25.4% | -0.8% |
Return vs Industry: 1IY underperformed the German Biotechs industry which returned -25.4% over the past year.
Return vs Market: 1IY underperformed the German Market which returned -0.8% over the past year.
Price Volatility
| 1IY volatility | |
|---|---|
| 1IY Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1IY's share price has been volatile over the past 3 months.
Volatility Over Time: 1IY's weekly volatility has decreased from 29% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 10 | Chandler Robinson | www.monopartx.com |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers.
Monopar Therapeutics Inc. Fundamentals Summary
| 1IY fundamental statistics | |
|---|---|
| Market cap | €7.59m |
| Earnings (TTM) | -€6.52m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs 1IY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1IY income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.12m |
| Earnings | -US$7.12m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.02 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1IY perform over the long term?
See historical performance and comparison